CTNNB1 and hepatocellular carcinoma: Note that ~27% of HCC cases (e.g., HepG2) contain mutations in CTNNB1 gene (encoding β-catenin), leading to aberrant activation of the Wnt/β-catenin pathway that is no longer affected by the protein destruction complex [44].